Precede Biosciences demonstrates accurate HER2 status detection in cancer patients, supporting relevance to 70+ therapeutics at ASCO 2024.
Precede Biosciences showcased data at ASCO 2024, demonstrating accurate HER2 status detection in 172 patients with advanced breast, gastroesophageal, and ovarian cancers, and quantifying ER pathway activation in 87 advanced breast cancer patients. The results support the relevance of their Precede Bio platform to the over 70 therapeutics targeting HER2 and ER pathway in active clinical development.
June 02, 2024
3 Articles